DURLAZA is indicated to: Reduce the risk of death and myocardial infarction (MI) in patients with chronic coronary artery disease, such as patients with a history of MI or unstable angina pectoris or with chronic stable angina Reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack Limitation of Use : Use immediate-release aspirin, not DURLAZA in situa...
The recommended dose of DURLAZA is one capsule (162.5 mg) once daily. Take the capsules with a full glass of water at the same time each day. Swallow DURLAZA capsules whole. Do not cut, crush or chew capsules. Do not take DURLAZA 2 hours before or 1 hour after consuming alcohol [see Warnings and Precautions (5) ] .
DURLAZA Capsules, 162.5 mg, are supplied as follows: Size 2 white to off-white opaque capsules imprinted with the name Durlaza Bottles of 30 capsules NDC 58487-001-01 Bottles of 90 capsules NDC 58487-001-02 Special Precautions for Storage: Store at 25 °C (77 °F); excursions permitted to 15 - 30°C (59 -86°F) [see USP Controlled Room Temperature].
www.newhavenpharma.com
www.fda.gov/medwatch
www.durlaza.comDURLAZA is indicated to:
Limitation of Use: Use immediate-release aspirin, not DURLAZA in situations where a rapid onset of action is required (such as acute treatment of myocardial infarction or before percutaneous coronary intervention).
The recommended dose of DURLAZA is one capsule (162.5 mg) once daily. Take the capsules with a full glass of water at the same time each day.
Swallow DURLAZA capsules whole. Do not cut, crush or chew capsules.
Do not take DURLAZA 2 hours before or 1 hour after consuming alcohol [see Warnings and Precautions (5)].
DURLAZA (aspirin) Extended Release Capsules are supplied as white to off-white opaque capsules each containing 162.5 mg of aspirin.
DURLAZA is contraindicated:
DURLAZA increases the risk of bleeding. Risk factors for bleeding include the use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7)].
DURLAZA may cause gastric ulceration and bleeding. Avoid DURLAZA in patients with active peptic ulcer disease.
DURLAZA can cause fetal harm when administered to a pregnant woman. Maternal aspirin use during later stages of pregnancy may cause low birth weight, increased incidence for intracranial hemorrhage in premature infants, stillbirths and neonatal death. Because NSAIDs may cause premature closure of the fetal ductus arteriosus, avoid DURLAZA in the third trimester of pregnancy [see Use in Specific Populations (8.1)].
The following is a list of adverse reactions that have been reported in the literature for products containing low dose aspirin [see Warnings and Precautions (5)].
Central Nervous System: Agitation, cerebral edema, coma, confusion, dizziness, headache, lethargy, seizures.
Fluid and Electrolyte: Hyperkalemia, metabolic acidosis, respiratory alkalosis.
Gastrointestinal: Dyspepsia, hepatic enzyme elevation, hepatitis, Reye's Syndrome.
Renal: Interstitial nephritis, papillary necrosis, proteinuria, renal insufficiency and failure.
Alcohol: Do not take DURLAZA 2 hours before or 1 hour after consuming alcohol. Alcohol can interfere with the controlled release properties of DURLAZA.
Renin-angiotensin system (RAS) inhibitors: In patients who are elderly, volume-depleted (including those on diuretic therapy), or who have compromised renal function, coadministration of NSAIDs, including DURLAZA, with RAS inhibitors may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving RAS inhibitors and DURLAZA.
NSAIDs, including DURLAZA may attenuate the antihypertensive effects of RAS inhibitors.
Anticoagulant and antiplatelets: Increased risk of bleeding
Anticonvulsants: Salicylate can displace protein-bound phenytoin and valproic acid, leading to a decrease in the total concentration of phenytoin and an increase in serum valproic acid levels.
Methotrexate: Salicylate can inhibit renal clearance of methotrexate, leading to bone marrow toxicity, especially in the elderly or renal impaired.
Nonsteroidal Anti-inflammatory Drugs (NSAIDs): The concurrent use of DURLAZA with other NSAIDs increases the risk of bleeding and may result in renal impairment.
Ibuprofen can interfere with the anti-platelet effect of low dose aspirin. Patients who use DURLAZA and take a single dose of ibuprofen 400 mg should dose the ibuprofen at least 2-4 hours or longer after ingestion of DURLAZA. Wait 8 hours after ibuprofen dosing, before giving aspirin, to avoid significant interference.
Nonselective NSAIDs may interfere with the antiplatelet effect of low-dose aspirin.
Avoid use during the third trimester of pregnancy because NSAIDs such as DURLAZA may cause premature closure of the fetal ductus arteriosus. Salicylate products have also been associated with alterations in maternal and neonatal hemostasis mechanisms, decreased birth weight, and with perinatal mortality.
Avoid DURLAZA 1 week prior to and during labor and delivery because it can result in excessive blood loss at delivery. Prolonged gestation and prolonged labor due to prostaglandin inhibition have been reported.
Because of the potential for serious adverse reactions in nursing infants from DURLAZA, choose either to discontinue DURLAZA or discontinue nursing.
Safety and effectiveness in pediatric patients have not been established.
In a large collaborative overview of aspirin for vascular event prevention, including over 14000 patients over 65 years of age, no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients.
Avoid DURLAZA in patients with severe hepatic insufficiency.
Avoid DURLAZA in patients with severe renal failure (glomerular filtration rate less than 10 mL/minute).
Salicylate toxicity may result from acute ingestion (overdose) or chronic intoxication. The early signs of salicylic overdose (salicylism), including tinnitus (ringing in the ears), occur at plasma concentrations approaching 200 mcg/mL. Plasma concentrations of aspirin above 300 mcg/mL are clearly toxic. Severe toxic effects are associated with levels above 400 mcg/mL [see Clinical Pharmacology (12.3)]. A single lethal dose of aspirin in adults is not known with certainty but death may be expected at 30 g. For real or suspected overdose, contact a Poison Control Center immediately.
Signs and Symptoms: In acute overdose, severe acid-base and electrolyte disturbances may occur and are complicated by hyperthermia and dehydration. Respiratory alkalosis occurs early while hyperventilation is present, but is quickly followed by metabolic acidosis.
Treatment: Treatment consists primarily of supporting vital functions, increasing salicylate elimination, and correcting the acid-base disturbance. Gastric emptying or lavage is recommended as soon as possible after ingestion, even if the patient has vomited spontaneously. After lavage or emesis, administer activated charcoal, as a slurry, if less than 3 hours have passed since ingestion.
Severity of aspirin intoxication is determined by measuring the blood salicylate level. Monitor acid-base status with serial blood gas and serum pH measurements. Maintain fluid and electrolyte balance.
In severe cases, hyperthermia and hypovolemia are the major immediate threats to life. Replace fluid intravenously and correct acidosis. Monitor plasma electrolytes and pH to promote alkaline diuresis of salicylate if renal function is normal. Glucose may be required to control hypoglycemia.
Hemodialysis and peritoneal dialysis can reduce the body aspirin content. In patients with renal insufficiency or in cases of life-threatening intoxication, dialysis is usually required. Exchange transfusion may be indicated in infants and young children.
DURLAZA Capsules contain aspirin, which is a platelet aggregation inhibitor, for oral administration. Chemically, aspirin is acetylsalicylic acid. It has the following structural formula:
Aspirin is white or almost white crystalline powder or colorless crystals consisting of cubical and squared crystals. It is slightly soluble in water, and soluble in ethanol. When exposed to moisture, aspirin hydrolyzes into salicylic and acetic acids, and gives off a vinegary odor. It has a molecular weight of 180.16 g/mole and a molecular formula C9H8O4.
Durlaza capsules also include the following inactive ingredients: ethylcellulose, povidone, castor oil, tartaric acid, magnesium stearate, colloidal anhydrous silica, and talc.
The capsule shell contains gelatin and titanium dioxide.
Aspirin [acetylsalicylic acid (ASA)] inhibits prostaglandin synthesis resulting in inhibition of platelet aggregation for their lifespan of about 7-10 days. The acetyl group of aspirin binds with a serine residue of cyclooxygenase-1 (COX-1), resulting in irreversible inactivation of the enzyme. Inhibition of COX-1 prevents conversion of arachidonic acid to thromboxane A2 (TXA2), which is a potent agonist of platelet aggregation.
The dose-response relationship for DURLAZA and immediate release (IR) aspirin towards COX-1 inhibition was characterized by examining the inhibition of serum TXB2 and urine 11-dehydro-TXB2 at 24 h following a single dose. Doses over the range of 20 mg to 325 mg for DURLAZA and 5 mg to 81 mg for IR aspirin respectively were studied. Half-maximal inhibition of serum TXB2 and urine 11-dehydro-TXB2 occurred with doses of DURLAZA (ID50) about 2-fold the dose of immediate release (IR) aspirin. Based on this relationship, the pharmacodynamic effect of DURLAZA 162.5 mg is similar to that attained with IR aspirin 81 mg. The mean inhibition of serum TXB2 following DURLAZA (82%) is lower when compared to IR aspirin 81 mg (93%) following the first dose. However, upon repeat administration, near maximal inhibition of serum TXB2 is achieved, similar to what is achieved following repeated daily doses of IR aspirin.
Following oral administration, DURLAZA exhibits extended release of aspirin from the encapsulated microparticles, thereby prolonging the absorption of aspirin across the GI tract compared to IR aspirin (Figure 1). Once absorbed, aspirin is metabolized, distributed, and excreted in a manner similar to that of aspirin absorbed from IR dosage forms.
Absorption: Following administration of DURLAZA, the time to reach peak plasma concentration of aspirin is slightly longer compared to following IR aspirin dosage form. Median Tmax for DURLAZA is about 2 h when compared to 1 h following IR aspirin (see Figure 1). The mean Cmax for DURLAZA is approximately 35% of that following IR aspirin 81 mg. The area under the plasma concentration-time curve for aspirin following administration of DURLAZA is approximately 70% of that following IR aspirin. The rate of DURLAZA absorption is dependent on food, alcohol, and gastric pH.
Distribution: The volume of distribution of usual doses of aspirin in normal subjects averages approximately 170 mL/kg of body weight.
Metabolism: Aspirin is rapidly hydrolyzed in the plasma to salicylic acid such that plasma levels of aspirin following DURLAZA administration are essentially undetectable 4-8 hours after dosing. In contrast to immediate release aspirin, measurable levels of salicylic acid at 24 hours following a single dose of DURLAZA were observed. Salicylic acid is primarily conjugated in the liver to form salicyluric acid, a phenolic glucuronide, an acyl glucuronide, and a number of minor metabolites.
Elimination: The mean plasma half-life of aspirin may range from 20 to 60 min. Following therapeutic doses, approximately 10% is found excreted in the urine as salicylic acid, 75% as salicylic acid, and 10% phenolic and 5% acyl glucuronides of salicylic acid.
No carcinogenesis, mutagenesis or impairment of fertility studies were conducted with DURLAZA. Aspirin is not considered to be genotoxic or carcinogenic. Studies with oral aspirin in pregnant rats demonstrated the occurrence of fetal malformations at oral doses at or above 250 mg/kg [Human equivalent dose (HED) 40 mg/kg].
A single oral dose of 2500 mg/kg (HED 405 mg/kg) DURLAZA was well-tolerated in the gastrointestinal tract of the rat whereas a single oral dose of IR aspirin ≥740 mg/kg (HED 120 mg/kg) caused lethality and gastric mucosal damage.
This indication is supported by the results of six large, randomized, multi-center, placebo controlled trials of predominantly male post-MI subjects and one randomized placebo-controlled study of men with unstable angina pectoris. Aspirin therapy in MI subjects gave about 20% reduction in the relative risk of the combined endpoint of death or nonfatal reinfarction. In the study of male unstable angina patients, aspirin reduced the event rate from 10% in the placebo patients to 5% in the patients treated with aspirin.
It is also supported by a randomized, multi-center, double-blind trial designed to assess the effect of aspirin in reducing the risk of MI in patients with chronic stable angina pectoris. Aspirin reduced the relative risk of the primary combined endpoint of nonfatal MI, fatal MI, and sudden death by 34%. The secondary endpoint for vascular events (the first occurrence of MI, stroke, or vascular death) was also significantly reduced.
In clinical trials of subjects with ischemic stroke or TIAs, aspirin has been shown to reduce the relative risk of the combined endpoint of stroke or death and the combined endpoint of TIA, stroke, or death by about 13 - 18%.
DURLAZA Capsules, 162.5 mg, are supplied as follows:
Size 2 white to off-white opaque capsules imprinted with the name Durlaza
Bottles of 30 capsules NDC 58487-001-01
Bottles of 90 capsules NDC 58487-001-02
Special Precautions for Storage: Store at 25 °C (77 °F); excursions permitted to 15 - 30°C (59 -86°F) [see USP Controlled Room Temperature].
Discuss the following with patients prior to initiating treatment with DURLAZA and periodically during the course of ongoing treatment:
Bleeding
Hypersensitivity
Alcohol Consumption
Administration Instructions
Pregnancy and Lactation
Manufactured for New Haven Pharmaceuticals, Inc.
North Haven, CT 06473
DURLAZA Capsules manufactured in USA
Distributed by Cardinal Health 105, Inc.
NDC 58487-001-02
DURLAZA™
(ASPIRIN)
Extended Release Capsules
162.5 mg
Rx Only
90 Capsules
DOSAGE: See package insert for full Prescribing Information.
Take DURLAZA once daily.
Swallow capsules whole.
Do not cut, crush or chew.
Each capsule contains 162.5 mg of aspirin.
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].
Keep out of reach of children.
www.durlaza.com
Manufactured for:
New Haven Pharmaceuticals, Inc.
North Haven, CT 06473
Made in USA
©2015 New Haven Pharmaceuticals, Inc.
19959
LOT:
EXP:
NDC 58487-001-01
DURLAZA™
(ASPIRIN)
Extended Release Capsules
162.5 mg
Rx Only
30 Capsules
DOSAGE: See package insert for full Prescribing Information.
Take DURLAZA once daily.
Swallow capsules whole.
Do not cut, crush or chew.
Each capsule contains 162.5 mg of aspirin.
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].
Keep out of reach of children.
Manufactured for:
New Haven Pharmaceuticals, Inc.
North Haven, CT 06473
Made in USA
www.durlaza.com
©2015 New Haven Pharmaceuticals, Inc.
19958
LOT:
EXP:
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 1665356 | aspirin 162.5 MG 24HR Extended Release Oral Capsule | PSN | 6 |
| 1665362 | Durlaza 162.5 MG 24HR Extended Release Oral Capsule | PSN | 6 |
| 1665362 | 24 HR aspirin 162.5 MG Extended Release Oral Capsule [Durlaza] | SBD | 6 |
| 1665356 | 24 HR aspirin 162.5 MG Extended Release Oral Capsule | SCD | 6 |
| 1665356 | 24 HR ASA 162.5 MG Extended Release Oral Capsule | SY | 6 |
| 1665362 | 24 HR ASA 162.5 MG Extended Release Oral Capsule [Durlaza] | SY | 6 |
| 1665356 | aspirin 162.5 MG 24HR Extended Release Oral Capsule | SY | 6 |
| 1665362 | Durlaza 162.5 MG 24HR Extended Release Oral Capsule | SY | 6 |
| Class | Version | Type | Effective |
|---|---|---|---|
| ASPIRIN Pharmacologic Class Indexing | 3 | Indexing - Pharmacologic Class | 20191108 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| d7724692-1155-4cc8-a415-22f5fc4aec35 | Product name | 6 | 20220216 |
| bde672ba-4805-28d0-1986-73543d41b412 | Product name | 2 | 20210201 |
| f52be47f-7aa7-46c0-b1fa-50c18dd50206 | Product name | 1 | 20201029 |
| f212291f-05fe-9603-fc7e-bd73e38ce1e6 | Product name | 2 | 20161129 |
| ade821ba-260a-47e2-bd89-743e27ac9906 | Product name | 1 | 20161121 |
| 182f9ab4-4ab5-c449-200f-87ce2ce8e550 | Product name | 2 | 20151105 |
| 9425d234-4ae1-4b53-adc6-8cc7af6dd657 | Product name | 1 | 20150929 |
| 2a21311a-89e2-0e83-2ebd-117f9798b2b2 | Product name | 1 | 20140508 |
| 9007e8a7-ff50-f9b9-7945-f2a1deadd94e | Product name | 1 | 20140508 |
| 96c2be53-8e44-452d-56a2-d255b2f1af2d | Product name | 1 | 20140508 |
| bf8bd5f7-495f-4022-2780-7ded7ea7ea44 | Product name | 1 | 20140508 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 58487-001-01 | DURLAZA | 30 in 1 BOTTLE | CAPSULE, EXTENDED RELEASE | 30 | 6 | |
| 58487-001-02 | DURLAZA | 90 in 1 BOTTLE | CAPSULE, EXTENDED RELEASE | 90 | 6 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 58487-001-01 | EA - Each | 58487-001 | 28da98b6-40cc-4572-9e78-c75d1a21a6b1 | 1 | 2015-10-02 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Aspirin | ACTIVE INGREDIENT | R16CO5Y76E | 6 | |
| Aspirin | ACTIVE MOIETY | R16CO5Y76E | 6 | |
| Castor Oil | INACTIVE INGREDIENT | D5340Y2I9G | 6 | |
| Ethylcelluloses | INACTIVE INGREDIENT | 7Z8S9VYZ4B | 6 | |
| Gelatin | INACTIVE INGREDIENT | 2G86QN327L | 6 | |
| Magnesium Stearate | INACTIVE INGREDIENT | 70097M6I30 | 6 | |
| Povidones | INACTIVE INGREDIENT | FZ989GH94E | 6 | |
| Silicon Dioxide | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 6 | |
| Talc | INACTIVE INGREDIENT | 7SEV7J4R1U | 6 | |
| Tartaric Acid | INACTIVE INGREDIENT | W4888I119H | 6 | |
| Titanium Dioxide | INACTIVE INGREDIENT | 15FIX9V2JP | 6 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 58487-001 | 58487-001-01, 58487-001-02 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| Aspirin | R16CO5Y76E | ACTIB |
| Ethylcelluloses | 7Z8S9VYZ4B | IACT |
| Povidones | FZ989GH94E | IACT |
| Castor Oil | D5340Y2I9G | IACT |
| Tartaric Acid | W4888I119H | IACT |
| Magnesium Stearate | 70097M6I30 | IACT |
| Silicon Dioxide | ETJ7Z6XBU4 | IACT |
| Talc | 7SEV7J4R1U | IACT |
| Gelatin | 2G86QN327L | IACT |
| Titanium Dioxide | 15FIX9V2JP | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | POWDER / ORAL | 2 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, EXTENDED RELEASE / ORAL | 67 mg | ||
| Povidones | POVIDONE | FZ989GH94E | INJECTION / INTRAMUSCULAR | 0.2 %w/v | ||
| Magnesium Stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, COATED / ORAL | 184 mg | ||
| Talc | TALC | 7SEV7J4R1U | ELIXIR / ORAL | 4.5 mg/5ml | ||
| Povidones | POVIDONE | FZ989GH94E | CAPSULE, DELAYED RELEASE PELLETS / ORAL | 32 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, COATED PELLETS / ORAL | 4.4 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED PELLETS / ORAL | 69 mg | ||
| Tartaric Acid | TARTARIC ACID | W4888I119H | CAPSULE / ORAL | 400 mg | ||
| Talc | TALC | 7SEV7J4R1U | SUSPENSION / ORAL | 234 mg | ||
| Gelatin | GELATIN | 2G86QN327L | SYSTEM / TOPICAL | 1050 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, DELAYED RELEASE PELLETS / ORAL | 24 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | CREAM / TOPICAL | 80 mg | ||
| Povidones | POVIDONE | FZ989GH94E | TABLET, FILM COATED / ORAL | 240 mg | ||
| Povidones | POVIDONE | FZ989GH94E | TABLET, FOR SUSPENSION / ORAL | 2 mg | ||
| Gelatin | GELATIN | 2G86QN327L | CAPSULE, DELAYED RELEASE / ORAL | 1791 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, COATED / ORAL | 49 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | FILM, EXTENDED RELEASE / TRANSDERMAL | 49 mg | ||
| Talc | TALC | 7SEV7J4R1U | CAPSULE / ORAL | 729 mg | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| Gelatin | GELATIN | 2G86QN327L | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 14 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / SUBLINGUAL | 10 mg | ||
| Castor Oil | CASTOR OIL | D5340Y2I9G | TABLET, FILM COATED / ORAL | 15.29 mg | ||
| Gelatin | GELATIN | 2G86QN327L | TABLET, ORALLY DISINTEGRATING / SUBLINGUAL | 13 mg | ||
| Talc | TALC | 7SEV7J4R1U | CAPSULE, COATED / ORAL | 87 mg | ||
| Magnesium Stearate | MAGNESIUM STEARATE | 70097M6I30 | POWDER, FOR SUSPENSION / ORAL | 120 mg | ||
| Talc | TALC | 7SEV7J4R1U | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 357 mg | ||
| Gelatin | GELATIN | 2G86QN327L | DROPS / NASAL | 50 mg/1ml | ||
| Tartaric Acid | TARTARIC ACID | W4888I119H | INJECTION, SOLUTION / SUBCUTANEOUS | 18 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 336 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | PELLET / ORAL | 34 mg | ||
| Talc | TALC | 7SEV7J4R1U | GRANULE, FOR SUSPENSION / ORAL | 296 mg | ||
| Povidones | POVIDONE | FZ989GH94E | POWDER, FOR SUSPENSION / ORAL | 35 mg/5ml | ||
| Titanium Dioxide | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, EXTENDED RELEASE / ORAL | 90 mg | ||
| Tartaric Acid | TARTARIC ACID | W4888I119H | INJECTION / INTRAVENOUS | 20 mg | ||
| Povidones | POVIDONE | FZ989GH94E | TABLET, CHEWABLE / ORAL | 48 mg | ||
| Magnesium Stearate | MAGNESIUM STEARATE | 70097M6I30 | GRANULE / ORAL | 629 mg | ||
| Povidones | POVIDONE | FZ989GH94E | SOLUTION / OPHTHALMIC | 1.8 %w/v | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, DELAYED RELEASE / ORAL | 1190 mg | ||
| Tartaric Acid | TARTARIC ACID | W4888I119H | TABLET / ORAL | 63 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / BUCCAL | 3 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| Gelatin | GELATIN | 2G86QN327L | CAPSULE / ORAL | 10932 mg | ||
| Gelatin | GELATIN | 2G86QN327L | INJECTION / INTRAVENOUS | 20 mg | ||
| Ethylcelluloses | ETHYLCELLULOSE | 7Z8S9VYZ4B | CREAM / TOPICAL | NA | ||
| Talc | TALC | 7SEV7J4R1U | LOZENGE / ORAL | 50 mg | ||
| Talc | TALC | 7SEV7J4R1U | TABLET, EXTENDED RELEASE / ORAL | 300 mg | ||
| Magnesium Stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, DELAYED RELEASE / ORAL | 144 mg | ||
| Castor Oil | CASTOR OIL | D5340Y2I9G | GRANULE, FOR SUSPENSION / ORAL | 128 mg | ||
| Gelatin | GELATIN | 2G86QN327L | DROPS / ORAL | NA | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, DELAYED RELEASE / ORAL | 3.2 mg | ||
| Talc | TALC | 7SEV7J4R1U | DROPS / ORAL | NA | ||
| Gelatin | GELATIN | 2G86QN327L | PASTILLE / ORAL | 143 mg | ||
| Gelatin | GELATIN | 2G86QN327L | SOLUTION / ORAL | 34.8 mg | ||
| Silicon Dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, EXTENDED RELEASE / ORAL | 450 mg | ||
| Povidones | POVIDONE | FZ989GH94E | TABLET, COATED / ORAL | 49.2 mg | ||
| Gelatin | GELATIN | 2G86QN327L | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 14 mg | ||
| Talc | TALC | 7SEV7J4R1U | TABLET, DELAYED RELEASE / ORAL | 349 mg | ||
| Gelatin | GELATIN | 2G86QN327L | TABLET, DELAYED RELEASE / ORAL | 19 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N200671-001 | DURLAZA | ASPIRIN | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD | 2015-09-04 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD | 2015-09-04 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD | 2015-09-04 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD | 2015-09-04 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD | 2015-09-04 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD | 2015-09-04 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD | 2015-09-04 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD | 2015-09-04 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD | 2015-09-04 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD | 2015-09-04 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD | 2015-09-04 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD | 2015-09-04 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD | 2015-09-04 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD | 2015-09-04 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD | 2015-09-04 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD | 2015-09-04 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD | 2015-09-04 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD, RS | 2015-09-04 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD, RS | 2015-09-04 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD, RS | 2015-09-04 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD, RS | 2015-09-04 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD, RS | 2015-09-04 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD, RS | 2015-09-04 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD, RS | 2015-09-04 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD, RS | 2015-09-04 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD, RS | 2015-09-04 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD, RS | 2015-09-04 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD, RS | 2015-09-04 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD, RS | 2015-09-04 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD, RS | 2015-09-04 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD | 2015-09-04 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD | 2015-09-04 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD | 2015-09-04 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD | 2015-09-04 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD | 2015-09-04 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD, RS | 2015-09-04 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD, RS | 2015-09-04 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD, RS | 2015-09-04 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD, RS | 2015-09-04 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD, RS | 2015-09-04 | 3a93d1ddd44b… | |
| 2022-10-28 04:53 UTC | 2022-10 | N200671-001 | DURLAZA | 162.5MG | CAPSULE, EXTENDED RELEASE / ORAL | RLD, RS | 2015-09-04 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 6461fd18-6b4d-809a-73f4-fd0c23a99291 | 4c2a1403-3862-1efd-0a91-444989222b37 | 2015-09-25 | Warnings, Adverse reactions | 6461fd18-6b4d-809a-73f4-fd0c23a99291 4c2a1403-3862-1efd-0a91-444989222b37 |
Adverse event summaries are temporarily unavailable. Other product information remains available.